First Line Ovarian Cancer Treatment - Cohort Study (ENCOURAGE)

ARCAGY/ GINECO GROUP

Status: Completed

Conditions: Epithelial Ovarian Cancer

Treatments: Drug: Bevacizumab

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT01832415

ENCOURAGE (GINECO-OV123)

Details and patient eligibility

About

The French cooperative group GINECO proposes to implement an observational study to describe a real situation, in daily practice tolerance and methods of administration of bevacizumab (Avastin ®)

Full description

Population: Patients aged 18 years and older with an epithelial ovarian cancer, fallopian tube or primary peritoneal or witch it was decided to initiate a process comprising of Bevacizumab (Avastin ®) in first-line therapy

Enrollment: 500 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients aged 18 years and over,
• Patients with an epithelial ovarian cancer, fallopian tube or peritoneal who will receive bevacizumab (Avastin ®) in first-line therapy
• Patients should be informed of the study orally and should not have any objection their data to be processed.

Exclusion criteria

• Patient participation in a clinical trial
• Patient non-affiliated to a social security scheme.

Trial design

500 participants in 1 patient group

Use of bevacizumab (Avastin ®) - First-line ovarian cancer

Description:

Patient receiving bevacizumab in ovarian cancer first line treatment

Treatment:

Drug: Bevacizumab